debate: optimal approach for the management of cll patients with del(17p) - ibrutinib
Published 8 years ago • 900 plays • Length 15:23Download video MP4
Download video MP3
Similar videos
-
13:55
debate: optimal approach for the management of cll patients with del(17p) - novel agents
-
14:21
debate: which is the optimal approach for cll? - fcr
-
21:05
cll: optimal approaches for patients with deletion 17p
-
12:08
debate: which is the optimal approach for cll? - br
-
19:42
treatment options for the young cll patient with deletion 17p: do they need a different approach?
-
10:30
leukemia patient story: my 1st symptoms for cll | stephen's story (1/5) | the patient story
-
53:03
talk by professor paul moss - cll treatment in 2022/23
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
14:48
debate: best frontline regimen for a cll patient aged 60 who requires therapy - ibrutinib
-
2:07
efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
-
1:00:19
the molecular twin platform: a multi-omic approach for predicting accurate clinical outcomes
-
11:23
debate: best approach for multiple relapsed cll after chemoimmunotherapy - kinase inhibitor
-
1:33
dr. zelenetz on treatment for patients with cll who fail on ibrutinib or idelalisib
-
21:19
cll: sequencing monotherapy vs. combination therapy
-
25:38
cll: chemotherapy and ibrutinib based regimens
-
1:37
acalabrutinib may be an alternative to ibrutinib for treatment of cll
-
6:45
zanubrutinib demonstrates superior pfs compared with ibrutinib for treatment of r/r cll and sll
-
14:02
debate: best frontline regimen for a cll patient aged 60 who requires therapy - fcr
-
0:55
dr. pinilla-ibarz on ibrutinib's efficacy in treating high-risk patients with cll
-
2:51
the optimum approach to frontline treatment of cll in 2021
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
27:18
novel treatment options in cll